These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21159882)

  • 21. Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected].
    Graf EH; Pace MJ; Peterson BA; Lynch LJ; Chukwulebe SB; Mexas AM; Shaheen F; Martin JN; Deeks SG; Connors M; Migueles SA; O'Doherty U
    PLoS One; 2013; 8(8):e71879. PubMed ID: 23951263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens.
    Zou C; Murakoshi H; Kuse N; Akahoshi T; Chikata T; Gatanaga H; Oka S; Hanke T; Takiguchi M
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selection and accumulation of an HIV-1 escape mutant by three types of HIV-1-specific cytotoxic T lymphocytes recognizing wild-type and/or escape mutant epitopes.
    Akahoshi T; Chikata T; Tamura Y; Gatanaga H; Oka S; Takiguchi M
    J Virol; 2012 Feb; 86(4):1971-81. PubMed ID: 22156528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
    Perdiguero B; Sánchez-Corzo C; Sorzano COS; Saiz L; Mediavilla P; Esteban M; Gómez CE
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30781504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes.
    Bennett MS; Joseph A; Ng HL; Goldstein H; Yang OO
    AIDS; 2010 Nov; 24(17):2619-28. PubMed ID: 20881472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Common antibody dependent cell mediated cytotoxicity (ADCC) antibody epitopes of HIV-1 CRF01_AE Env and Gag in early HIV-1 infected individuals.
    Sangjan S; Ampol S; Tabprasit S; Horthongkham N; Chuenchitra T; Ekpo P; Kantakamalakul W
    Asian Pac J Allergy Immunol; 2019 Mar; 37(1):43-50. PubMed ID: 29602284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Gag sequence variability on level, phenotype, and function of anti-HIV Gag-specific CD8(+) cytotoxic T lymphocytes in untreated chronically HIV-infected patients.
    López M; Soriano V; Lozano S; Martinez P; Sempere J; González-Lahoz J; Benito J
    AIDS Res Hum Retroviruses; 2006 Sep; 22(9):884-92. PubMed ID: 16989614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential impact of magnitude, polyfunctional capacity, and specificity of HIV-specific CD8+ T cell responses on HIV set point.
    Riou C; Burgers WA; Mlisana K; Koup RA; Roederer M; Abdool Karim SS; Williamson C; Gray CM
    J Virol; 2014 Feb; 88(3):1819-24. PubMed ID: 24227857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and characterization of highly immunogenic and broadly recognized mimics of the HIV-1 CTL epitope Gag77-85.
    Boggiano C; Moya R; Pinilla C; Bihl F; Brander C; Sidney J; Sette A; Blondelle SE
    Eur J Immunol; 2005 May; 35(5):1428-37. PubMed ID: 15789356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel cytotoxic T-lymphocyte escape mutation by a three-amino-acid insertion in the human immunodeficiency virus type 1 p6Pol and p6Gag late domain associated with drug resistance.
    Cao J; McNevin J; McSweyn M; Liu Y; Mullins JI; McElrath MJ
    J Virol; 2008 Jan; 82(1):495-502. PubMed ID: 17942528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stem Cell-Derived Viral Antigen-Specific T Cells Suppress HIV Replication and PD-1 Expression on CD4+ T Cells.
    Haque M; Lei F; Xiong X; Ren Y; Peng HY; Wang L; Kumar A; Das JK; Song J
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33923025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Viral evolution in HLA-B27-restricted CTL epitopes in human immunodeficiency virus type 1-infected individuals.
    Setiawan LC; Gijsbers EF; van Nuenen AC; Kootstra NA
    J Gen Virol; 2015 Aug; 96(8):2372-2380. PubMed ID: 25872744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers.
    Ferre AL; Lemongello D; Hunt PW; Morris MM; Garcia JC; Pollard RB; Yee HF; Martin JN; Deeks SG; Shacklett BL
    J Virol; 2010 Oct; 84(19):10354-65. PubMed ID: 20668079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of Gag and Nef-specific ELISpot-based CTL responses in HIV-1 infected Indian individuals.
    Mendiratta S; Vajpayee M; Malhotra U; Kaushik S; Dar L; Mojumdar K; Chauhan NK; Sreenivas V
    Med Microbiol Immunol; 2009 Feb; 198(1):47-56. PubMed ID: 18985383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Balancing reversion of cytotoxic T-lymphocyte and neutralizing antibody escape mutations within human immunodeficiency virus type 1 Env upon transmission.
    Peut V; Campbell S; Gaeguta A; Center RJ; Wilson K; Alcantara S; Fernandez CS; Purcell DF; Kent SJ
    J Virol; 2009 Sep; 83(17):8986-92. PubMed ID: 19515763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Mutations on Replicative Fitness and Major Histocompatibility Complex Class I Binding Affinity Are Among the Determinants Underlying Cytotoxic-T-Lymphocyte Escape of HIV-1 Gag Epitopes.
    Du Y; Zhang TH; Dai L; Zheng X; Gorin AM; Oishi J; Wu TT; Yoshizawa JM; Li X; Yang OO; Martinez-Maza O; Detels R; Sun R
    mBio; 2017 Nov; 8(6):. PubMed ID: 29184023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection.
    Hay CM; Ruhl DJ; Basgoz NO; Wilson CC; Billingsley JM; DePasquale MP; D'Aquila RT; Wolinsky SM; Crawford JM; Montefiori DC; Walker BD
    J Virol; 1999 Jul; 73(7):5509-19. PubMed ID: 10364299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The antiviral activity of HIV-specific CD8+ CTL clones is limited by elimination due to encounter with HIV-infected targets.
    McKinney DM; Lewinsohn DA; Riddell SR; Greenberg PD; Mosier DE
    J Immunol; 1999 Jul; 163(2):861-7. PubMed ID: 10395680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel recombinant bacterial vaccine strain expressing dual viral antigens induces multiple immune responses to the Gag and gp120 proteins of HIV-1 in immunized mice.
    Feng Y; Wang S; Luo F; Ruan Y; Kang L; Xiang X; Chao T; Peng G; Zhu C; Mu Y; Zhu Y; Zhang X; Wu J
    Antiviral Res; 2008 Dec; 80(3):272-9. PubMed ID: 18639586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consequences of HLA-B*13-Associated Escape Mutations on HIV-1 Replication and Nef Function.
    Shahid A; Olvera A; Anmole G; Kuang XT; Cotton LA; Plana M; Brander C; Brockman MA; Brumme ZL
    J Virol; 2015 Nov; 89(22):11557-71. PubMed ID: 26355081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.